Quick Answer
Spero Therapeutics, Inc. reported Net Income of -$41.66 million for fiscal year 2018.
Spero Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2018 | -$41.66M | -7.5% |
| 2017 | -$38.74M | -52.0% |
| 2016 | -$25.49M | -151.0% |
| 2015 | -$10.15M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2018 | -$10.46M | -6.4% | -5.1% |
| June 30, 2018 | -$9.96M | -8.6% | +6.5% |
| March 31, 2018 | -$10.64M | -81.1% | -8.2% |
| September 30, 2017 | -$9.84M | -55.7% | -7.3% |
| June 30, 2017 | -$9.17M | — | -56.0% |
| March 31, 2017 | -$5.88M | — | +7.0% |
| September 30, 2016 | -$6.32M | — | — |
- Spero Therapeutics, Inc. showed a decrease of -7.5% in Net Income compared to the prior fiscal year.
- Over the 2015–2018 period, Spero Therapeutics, Inc.’s net income has declined by 310.3% (from -$10.15 million to -$41.66 million).
- The most recent figure is from Spero Therapeutics, Inc.’s fiscal year 2018 report (Form 10-K), filed with the SEC on March 14, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: